ArticleCancers2019
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Cerebellar glioblastoma in adults: a comparative single-center matched pair analysis and systematic review of the literature.Journal of cancer research and clinical oncology · 2024Pooled it
- Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection.Journal of neuro-oncology · 2019Trial
- Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival.Journal of neuro-oncology · 2026Article
- Innovative Therapeutic Strategies Targeting the Network Architecture of Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres.Neuro-oncology · 2025Article
- Tonabersat enhances temozolomide-mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition.Molecular oncology · 2025Article
- Flow cytometry protocol for cell death analysis in glioblastoma organoids: A technical note.PloS one · 2025Article
- Current status of precision oncology in adult glioblastoma.Molecular oncology · 2024Review
- The Alcatraz-Strategy: a roadmap to break the connectivity barrier in malignant brain tumours.Molecular oncology · 2024Review
- Neural Influences on Tumor Progression Within the Central Nervous System.CNS neuroscience & therapeutics · 2024Review
- Central nervous system regulation of diffuse glioma growth and invasion: from single unit physiology to circuit remodeling.Journal of neuro-oncology · 2024Review
- The Potential Role of the Extracellular Matrix Glycoprotein Reelin in Glioblastoma Biology.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.Current issues in molecular biology · 2024Review
- Intrinsic and Microenvironmental Drivers of Glioblastoma Invasion.International journal of molecular sciences · 2024Review
- Connexins Control Glial Inflammation in Various Neurological Diseases.International journal of molecular sciences · 2023Review
- Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma.Neuro-oncology · 2023Article
- Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.Cellular and molecular neurobiology · 2023Review
- Brain Tumor Networks in Diffuse Glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Glioblastoma Microenvironment and Cellular Interactions.Cancers · 2022Review
- Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.Neuro-oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
Gap junctions have recently been shown to interconnect glioblastoma cells to a multicellular syncytial network, thereby allowing intercellular communication over long distances as well as enabling glioblastoma cells to form routes for brain microinvasion. Against this backdrop gap junction-targeted therapies might provide for an essential contribution to isolate cancer cells within the brain, thus increasing the tumor cells' vulnerability to the standard chemotherapeutic agent temozolomide. By utilizing INI-0602-a novel gap junction inhibitor optimized for crossing the blood brain barrier-in an oncological setting, the present study was aimed at evaluating the potential of gap junction-targeted therapy on primary human glioblastoma cell populations. Pharmacological inhibition of gap junctions profoundly sensitized primary glioblastoma cells to temozolomide-mediated cell death. On the molecular level, gap junction inhibition was associated with elevated activity of the JNK signaling pathway. With the use of a novel gap junction inhibitor capable of crossing the blood-brain barrier-thus constituting an auspicious drug for clinical applicability-these results may constitute a promising new therapeutic strategy in the field of current translational glioblastoma research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.